bioCongress

  • 2022年6月21-23日
  • 上海新国际博览中心N5馆

王宾

演讲嘉宾

演讲主题 PRESENTATION TOPIC

新冠DNA疫苗的快速研发
Applications of gene-edited humanized mice for drug discovery

王宾

王宾
特聘教授/共同创始人
复旦大学/艾棣维欣生物

 

Bin Wang
Distinguished Professor/ Co-Founder
Fudan University/ Advaccine Biotech

王宾,博士,特聘教授,博士生导师,艾棣维欣生物技术公司共同创始人。美国辛辛那提大学儿童医院博士; 美国Wistar研究所博士后;曾任美国宾夕法尼亚大学医学院任助研和助教授、新疆大学特聘教授、中国农业大学特聘教授。现任复旦大学特聘教授、国际疫苗研究所(IVI)科学委员会委员、国际疫苗学会会员、美国免疫学会会员、国际DNA疫苗学会理事,以及《DNA & Cell Biology》、《Human Vaccines & Immunotherapeutics》和《Emerging Microbes & Infections 》《中华微生物学和免疫学杂志》和《微生物学报》等杂志的编委会委员。主要研究领域:DNA 疫苗、新型疫苗佐剂研究,治疗性疫苗等研究。

 

自1995年以来,发表了150多篇SCI论文,获得了美国等各国发明专利35项、中国发明专利22项。完成一种新型佐剂的科研部级鉴定和农业部批准新型佐剂进入临床试验。完成二项人用治疗性疫苗佐剂临床研究、完成了一项新型RSV疫苗、新冠DNA疫苗项目进入临床试验,完成了一项临床免疫学检测平台建立。发明的免疫耐受疫苗专利技术,在全世界40多个国家申请,并完成了7项相关发明专利项目的技术转让。主持和参与了国家“863”重大项目、自然科学基金重点项目、传染病重大专项和新药创制专项等国家及省部级科研课题40多项。获得科学中国人2015年度人物奖和3项发明专利金奖。

 

BIN WANG, Ph.D.

Dr. Bin Wang is a distinguished professor at Department of Medical Microbiology and Parasitology, Fudan University School of Basic Medical Sciences. He is also a co-founder of Advaccine Biotech in China. His research area is to focus on the development of DNA vaccines against various diseases, including the SARS-CoV2, therapeutics and novel vaccine adjuvants. Those developments are achieved into several ongoing clinical trials, including a COVID 19 vaccine, an RSV vaccine, and an HBV therapeutic vaccine.

 

He received his B.A. in biology from Shandong University in 1982 and his Ph.D. from the Cincinnati Children Hospital at University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute 1992. He became an instructor and then assistant professor at University of Pennsylvania Medical School in the period of 1993 to 1998. He was a professor and served as the Chairman at Department of Microbiology and Immunology for 6 years at College of Biological Sciences, China Agricultural University before he joined to Fudan University. He was one of very early DNA vaccine technology inventors in 90’s and performed the first-in human DNA vaccine trials in 1994-1996. He has published over 150 peer-review articles and awarded 35 US and 22 Chinese patents. He serves as editorial board members for several international journals and executive members in number of scientific societies.